196 related articles for article (PubMed ID: 27206681)
1. Innate signaling by mycobacterial cell wall components and relevance for development of adjuvants for subunit vaccines.
Tima HG; Huygen K; Romano M
Expert Rev Vaccines; 2016 Nov; 15(11):1409-1420. PubMed ID: 27206681
[TBL] [Abstract][Full Text] [Related]
2. Targeting Syk-Card9-activating C-type lectin receptors by vaccine adjuvants: findings, implications and open questions.
Lang R; Schoenen H; Desel C
Immunobiology; 2011 Nov; 216(11):1184-91. PubMed ID: 21742403
[TBL] [Abstract][Full Text] [Related]
3. Rational design of adjuvants targeting the C-type lectin Mincle.
Decout A; Silva-Gomes S; Drocourt D; Barbe S; André I; Cueto FJ; Lioux T; Sancho D; Pérouzel E; Vercellone A; Prandi J; Gilleron M; Tiraby G; Nigou J
Proc Natl Acad Sci U S A; 2017 Mar; 114(10):2675-2680. PubMed ID: 28223515
[TBL] [Abstract][Full Text] [Related]
4. Novel lipopeptides of ESAT-6 induce strong protective immunity against Mycobacterium tuberculosis: Routes of immunization and TLR agonists critically impact vaccine's efficacy.
Gupta N; Vedi S; Kunimoto DY; Agrawal B; Kumar R
Vaccine; 2016 Nov; 34(46):5677-5688. PubMed ID: 27693020
[TBL] [Abstract][Full Text] [Related]
5. A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice.
Liu X; Da Z; Wang Y; Niu H; Li R; Yu H; He S; Guo M; Wang Y; Luo Y; Ma X; Zhu B
Vaccine; 2016 Mar; 34(11):1370-8. PubMed ID: 26845736
[TBL] [Abstract][Full Text] [Related]
6. Potential of Cationic Liposomes as Adjuvants/Delivery Systems for Tuberculosis Subunit Vaccines.
Khademi F; Taheri RA; Momtazi-Borojeni AA; Farnoosh G; Johnston TP; Sahebkar A
Rev Physiol Biochem Pharmacol; 2018; 175():47-69. PubMed ID: 29700609
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol di-mannoside and derivates modulate the immune response to and efficacy of a tuberculosis protein vaccine against Mycobacterium bovis infection.
Parlane NA; Compton BJ; Hayman CM; Painter GF; Basaraba RJ; Heiser A; Buddle BM
Vaccine; 2012 Jan; 30(3):580-8. PubMed ID: 22120192
[TBL] [Abstract][Full Text] [Related]
8. Selection of adjuvants for vaccines targeting specific pathogens.
Sarkar I; Garg R; van Drunen Littel-van den Hurk S
Expert Rev Vaccines; 2019 May; 18(5):505-521. PubMed ID: 31009255
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and protective efficacy of novel Mycobacterium tuberculosis antigens.
Derrick SC; Yabe IM; Yang A; Kolibab K; Hollingsworth B; Kurtz SL; Morris S
Vaccine; 2013 Sep; 31(41):4641-6. PubMed ID: 23906890
[TBL] [Abstract][Full Text] [Related]
10. Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists.
Collier MA; Junkins RD; Gallovic MD; Johnson BM; Johnson MM; Macintyre AN; Sempowski GD; Bachelder EM; Ting JP; Ainslie KM
Mol Pharm; 2018 Nov; 15(11):4933-4946. PubMed ID: 30281314
[TBL] [Abstract][Full Text] [Related]
11. Immunological Mechanism and Clinical Application of PAMP Adjuvants.
Yan Y; Yao D; Li X
Recent Pat Anticancer Drug Discov; 2021; 16(1):30-43. PubMed ID: 33563182
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory Properties and Adjuvant Potential of Synthetic Glycolipids Homologous to Mycolate Esters of the Cell Wall of Mycobacterium tuberculosis.
Tima HG; Al Dulayymi JR; Denis O; Lehebel P; Baols KS; Mohammed MO; L'Homme L; Sahb MM; Potemberg G; Legrand S; Lang R; Beyaert R; Piette J; Baird MS; Huygen K; Romano M
J Innate Immun; 2017; 9(2):162-180. PubMed ID: 27855374
[TBL] [Abstract][Full Text] [Related]
13. Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.
Kaur A; Kannan D; Mehta SK; Singh S; Salunke DB
Expert Opin Ther Pat; 2018 Nov; 28(11):837-847. PubMed ID: 30280939
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice.
Li Q; Yu H; Zhang Y; Wang B; Jiang W; Da Z; Xian Q; Wang Y; Liu X; Zhu B
Scand J Immunol; 2011 Jun; 73(6):568-76. PubMed ID: 21323695
[TBL] [Abstract][Full Text] [Related]
15. Exploration of Pattern Recognition Receptor Agonists as Candidate Adjuvants.
Ong GH; Lian BSX; Kawasaki T; Kawai T
Front Cell Infect Microbiol; 2021; 11():745016. PubMed ID: 34692565
[TBL] [Abstract][Full Text] [Related]
16. Recognition of Mycobacterial Lipids by Immune Receptors.
Ishikawa E; Mori D; Yamasaki S
Trends Immunol; 2017 Jan; 38(1):66-76. PubMed ID: 27889398
[TBL] [Abstract][Full Text] [Related]
17. Microstructured liposome subunit vaccines reduce lung inflammation and bacterial load after Mycobacterium tuberculosis infection.
Trentini MM; de Oliveira FM; Gaeti MP; Batista AC; Lima EM; Kipnis A; Junqueira-Kipnis AP
Vaccine; 2014 Jul; 32(34):4324-32. PubMed ID: 24951861
[TBL] [Abstract][Full Text] [Related]
18. Heat killed Saccharomyces cerevisiae as an adjuvant for the induction of vaccine-mediated immunity against infection with Mycobacterium tuberculosis.
Grover A; McLean JL; Troudt JM; Foster C; Izzo L; Creissen E; MacDonald E; Troy A; Izzo AA
Vaccine; 2016 May; 34(25):2798-805. PubMed ID: 27131285
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of adjuvants for protein vaccines against tuberculosis in guinea pigs.
Hogarth PJ; Jahans KJ; Hecker R; Hewinson RG; Chambers MA
Vaccine; 2003 Feb; 21(9-10):977-82. PubMed ID: 12547611
[TBL] [Abstract][Full Text] [Related]
20. PAMPs of the Fungal Cell Wall and Mammalian PRRs.
Hatinguais R; Willment JA; Brown GD
Curr Top Microbiol Immunol; 2020; 425():187-223. PubMed ID: 32180018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
